Jasper Therapeutics, Inc. Securities Lawsuit Investigation

Shamis & Gentile P.A., one of the nation's premier class action law firms specializing in securities fraud cases, is investigating potential claims against Jasper Therapeutics, Inc. (JSPR)

If you purchased or acquired Jasper Therapeutics, Inc. securities between November 30, 2023 and July 3, 2025, you may be eligible to join this class action lawsuit and seek compensation for your losses.

About Jasper Therapeutics

Jasper Therapeutics is a biotechnology company focused on developing therapies for diseases driven by mast and stem cells. The company’s primary mission is to create safer and potentially curative treatments for patients who have limited options, particularly in areas such as chronic urticaria and asthma.

Jasper’s lead product candidate, briquilimab, is designed as a monoclonal antibody targeting the stem cell factor pathway.

The company has conducted several clinical trials, including the BEACON study for chronic spontaneous urticaria (CSU) and the ETESIAN study for asthma. Jasper does not own its own manufacturing facilities and relies on third-party manufacturers for its clinical drug supply.

The Allegations

The class action lawsuit alleges that Jasper Therapeutics and certain executives made materially false and misleading statements, or failed to disclose crucial information, during the class period from November 30, 2023 to July 3, 2025.

The complaint claims that Jasper did not have adequate controls and procedures in place to ensure that its third-party manufacturers were producing products in full compliance with current Good Manufacturing Practices (cGMP) regulations.

This alleged lack of oversight led to a significant issue: a defective lot of drug product was used in key clinical trials, including the BEACON and ETESIAN studies.

As a result, clinical trial data became confounded, undermining the reliability of the results and overstating the company’s business and financial prospects. The company eventually disclosed that this manufacturing issue forced it to halt multiple development programs and implement significant cost-cutting measures.

The truth came to light on July 7, 2025, when Jasper announced the drug lot issue and the impact on its clinical programs. On that news, Jasper’s stock price plummeted by 55.1%, closing at $3.04 per share, down from $6.77 the previous day.

This sharp decline represented a substantial loss for investors and was far greater than the overall market movement at the time.

Important Dates

• Class period: November 30, 2023 to July 3, 2025
• Lead plaintiff deadline: November 18, 2025
• Complaint filed: September 19, 2025

Your Rights and Next Steps

If you purchased or acquired Jasper Therapeutics securities during the class period, you have important legal rights. Investors who suffered losses due to the alleged misconduct may be eligible to join the class action lawsuit.

Joining a class action allows you to seek compensation for your losses alongside other affected investors.

To participate, you do not need to take any action to remain a potential class member; however, if you wish to serve as the lead plaintiff (the representative party who acts on behalf of other class members) you must file a motion with the court by November 18, 2025.

The lead plaintiff is typically the investor with the largest financial interest in the case and is responsible for directing the litigation.

Lawyers are ready to help review your situation, explain your rights, and guide you through the process. You can submit your information using the form below to determine your eligibility and take the next step toward potential recovery.

You May Be Entitled to Compensation

If you invested in Jasper Therapeutics during the class period and suffered financial losses, you may be entitled to compensation.

Completing the below form is the first step in joining the lawsuit and protecting your rights as an investor. Lawyers are ready to help you understand your options and pursue the recovery you deserve.